The bill H. 3096 aims to regulate gene therapy products in South Carolina by adding Chapter 141 to Title 44 of the South Carolina Code of Laws. It establishes definitions for terms related to gene therapy, such as "gene therapy product," "genetically modified," and "expose." The bill mandates that any product that could potentially act as a gene therapy or alter genetic material must be labeled as a "Potential Gene Therapy Product," while products confirmed to be gene therapy must be labeled as "Gene Therapy Product." The legislation emphasizes the importance of disclosure and requires that the labeling provisions be interpreted broadly to favor transparency.

Additionally, the bill stipulates that manufacturers, sellers, or distributors of products that could expose individuals to genetically modified material must provide information upon written request from residents. This includes details on how individuals may be exposed to the product, and the entities must respond within twenty-one days. Furthermore, the bill requires that fully informed consent be obtained from individuals who may be exposed to such products, ensuring they are aware of all benefits, risks, and potential side effects before any exposure occurs. The act will take effect upon the Governor's approval.